StreetInsider.com News Articles

Form 8-K MIRA PHARMACEUTICALS, For: Sep 17

Thu, 17 Sep 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260917/27073236.html

MIRA Pharmaceuticals submits Ketamir-2 Phase 2a protocol for IRB review

Thu, 17 Sep 2026 08:30:30 -0400

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced that its Phase 2a clinical protocol for Ketamir-2, an oral NMDA receptor modulator, has been submitted for Institutional Review Board (IRB) review at a cancer research institution, following feedback from the U.S. Food and Drug Administration.

The company is targeting site initiation in the first quarter of 2027, subject to IRB approval and standard site activation requirements. The study will be the first clinical evaluation of Ketamir-2 in patients with chemotherapy-induced peripheral neuropathy (CIPN).

The Phase 2a study is designed as a randomized, double-blind, placebo-controlled, three-period crossover trial enrolling adults with moderate-to-severe persistent CIPN. Participants will

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review

Thu, 17 Sep 2026 08:30:00 -0400

Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site Initiation

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and comments from the U.S. Food and Drug Administration (FDA), the Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) has been submitted for Institutional Review Board (IRB) review at a leading cancer research institution.

MIRA incorporated the FDA's feedback into the protocol and is targeting site initiation in the

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review

Thu, 17 Sep 2026 08:30:00 -0400

Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site Initiation

MIRA incorporated the FDA's feedback into the protocol and is targeting site initiation in the

Maxim Group Starts MIRA Pharmaceuticals Inc (MIRA) at Buy

Thu, 17 Sep 2026 07:46:27 -0400

Maxim Group analyst Jason McCarthy initiates coverage on MIRA Pharmaceuticals Inc (NASDAQ: MIRA) with a Buy rating and a price target of $3.50.

For an analyst ratings summary and ratings history on MIRA Pharmaceuticals Inc click here. For more ratings news on MIRA Pharmaceuticals Inc click here.

Shares of MIRA Pharmaceuticals Inc closed at $0.72 yesterday.

Form 8-K MIRA PHARMACEUTICALS, For: Sep 11

Wed, 16 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260916/27070699.html

Miravalles Gold Corp. Files NI 43-101 Technical Report for Fairfield Gold Project, Nayarit, Mexico

Thu, 03 Sep 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Miravalles Gold Corp. (CSE: MIRA) (OTC Pink: SSRSF) (the "Company" or "Miravalles") announces the filing of an independent technical report for its Fairfield Gold Project (the "Project") in Nayarit, Mexico.

The report, titled Technical Report on the Fairfield Gold Project, has an effective date of July 31, 2026, and was prepared by Warren Robb, P.Geo., an independent Qualified Person as defined by NI 43-101. It is available under the Company's issuer profile on SEDAR+ at www.sedarplus.ca.

The Fairfield Gold Project comprises five mineral concessions totalling 1,012.73 hectares in the municipalities of Compostela

Miravalles Gold Corp. Files NI 43-101 Technical Report for Fairfield Gold Project, Nayarit, Mexico

Thu, 03 Sep 2026 08:00:00 -0400

The Fairfield Gold Project comprises five mineral concessions totalling 1,012.73 hectares in the municipalities of Compostela

MIRA Pharmaceuticals reports positive toxicology data for MIRA-55 pain drug

Tue, 01 Sep 2026 08:03:28 -0400

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced positive results from 7-day dose-range finding toxicology and toxicokinetic studies of its investigational drug candidate MIRA-55, an oral non-opioid compound being developed for inflammatory pain.

The studies, conducted in rats and dogs, characterized tolerability, toxicity, and systemic exposure across both species. Rats were identified as the more sensitive species, while dogs demonstrated greater tolerance across the dose levels studied. Toxicokinetic analyses confirmed systemic exposure in both species and characterized how exposure changed with dose and repeated administration.

The company said the findings will be used to guide dose selection for the next phase of its IND-enabling

MIRA Pharmaceuticals reports positive toxicology data for MIRA-55 pain drug

Tue, 01 Sep 2026 08:03:28 -0400

The company said the findings will be used to guide dose selection for the next phase of its IND-enabling

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

Tue, 01 Sep 2026 08:00:00 -0400

Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission

MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs. MIRA-55 is the Company's investigational oral, non-opioid drug candidate being developed for inflammatory pain.

Cross-Species Study Findings

The completed studies characterized tolerability, toxicity, and systemic exposure across

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

Tue, 01 Sep 2026 08:00:00 -0400

Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND Submission

Cross-Species Study Findings

The completed studies characterized tolerability, toxicity, and systemic exposure across

Form 10-Q MIRA PHARMACEUTICALS, For: Jun 30

Wed, 12 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260812/26913194.html

Form 10-Q MIRA PHARMACEUTICALS, For: Jun 30

Wed, 12 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260812/26913194.html

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1